Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?

One multi-cancer early detection (MCED) test company's stock has soared 171% over the last six months, but is up a more modest 64% overall in 2026. The discrepancy in Grail's (NASDAQ: GRAL) stock performance reflects a strong recovery from the tumultuous events of mid-February, when the company announced it had missed the primary endpoint in a landmark trial. The underlying causes behind this volatility are likely to play out in deciding where the company will be over the next half-decade.

What Wall Street expects from Grail

Let's start by looking at some numbers, and then get into the key detail: what to believe in the numbers.

As you can see below, Grail isn't profitable or cash-generative yet, and according to Wall Street, it won't be until 2032/2033. That might make the stock look unattractive to many. However, it's worth considering that, under these estimates, revenue will grow at a 30% rate as its MCED test, Galleri, continues to gain adoption by medical insurers, and test sales balloon from 247,000 in 2026 to 832,0000 in 2030.

Moreover, diagnostic test sales tend to be recurring due to repeat testing as part of annual screening protocols and growth in insurance coverage. As such, the market will always take a forward-looking view of Grail's prospects, with an eye on long-term free cash flow generation.

Data source: Visible Alpha Wall Street consensus.

What really guides Grail's prospects

Analyst estimates are one thing, but the underlying assumptions needed to believe them are another. The key question that determines whether Grail's revenue will be $300 million, $500 million, or $700 million in 2030 is the rate of adoption of the Galleri test.

That debate is likely to be settled in the spreadsheets of medical insurers as they weigh the benefits of the MCED test against its costs. Naturally, those decisions will be guided by clinical data and supporting evidence. They will also be driven by whether the U.S. Food and Drug Administration (FDA) grants Grail premarket approval.

The latter moved a step closer to fruition recently, with news that the FDA's Medical Devices Advisory Committee's Molecular and Clinical Genetics Devices Panel voted favorably on Grail's safety, benefit, and effectiveness. The market wasted no time pricing in the assumption that the FDA would ultimately grant approval based on that vote.

The stock's surge marked a remarkable recovery from the February slump, following Grail's report that "The primary endpoint of statistically significant Stage III-IV reduction was not observed" in its three-year, 142,000-patient trial with England's National Health Service (NHS).

The debate around Galleri

Returning to the cost/benefit analysis on insurers' spreadsheets, the crux of the argument boils down to whether insurers see the benefits of Galleri's strength in early detection in the 12 most deadly cancers that cause two-thirds of cancer-related deaths as more beneficial than the cost of the test, alternatives, and the cost of testing the false positives of the Galleri test.

False positives are a major issue, as every positive result from Galleri triggers further, often expensive, testing. On the benefit side, early cancer detection not only leads to better patient outcomes and less invasive, less painful treatment, but also costs significantly less than late-stage treatment.

Image source: Getty Images.

Some of the data from the NHS trial and the 35,878-patient trial in the U.S., Pathfinder 2, are shown below. Episode sensitivity measures the percentage of cancers detected among those confirmed with cancer within 12 months, and it clearly indicates that Galleri is better at detecting the 12 deadliest cancers.

Predictive positive value measures the percentage of true positives among positive Galleri results. A high rate implies fewer false positives among the "positive" results. Specificity measures the percentage of people who take the test and get a correct negative result. Finally, cancer signal origin accuracy measures the test's ability to predict the cancer's location.

Data source: Grail presentations.

Where next for Galleri?

Whether this data, and a host of other data, are sufficient to justify adopting Galleri, or even adopting it at the near-$1,000 test price point, is a matter for debate. The pace of adoption is also a moot point. Ultimately, the key decisions will be made by insurers, but if you are uncomfortable with the data, then Grail might not be a stock for you for the next five years. Alternatively, the reverse holds.

Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Grail. The Motley Fool has a disclosure policy.